Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Ba27f93032f4f7d0d0ec62863da4e3da8> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Ba27f93032f4f7d0d0ec62863da4e3da8 NCIT_P378 "NCI" @default.
- Ba27f93032f4f7d0d0ec62863da4e3da8 type Axiom @default.
- Ba27f93032f4f7d0d0ec62863da4e3da8 annotatedProperty IAO_0000115 @default.
- Ba27f93032f4f7d0d0ec62863da4e3da8 annotatedSource NCIT_C176563 @default.
- Ba27f93032f4f7d0d0ec62863da4e3da8 annotatedTarget "An orally bioavailable, selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon oral administration, LY3405105 selectively targets, binds to and inhibits the activity of CDK7, thereby inhibiting CDK7-mediated signaling. Specifically, inhibition of CDK7 prevents phosphorylation of the carboxy-terminal domain (CTD) of RNA Polymerase II, thereby preventing transcription of important cancer-promoting genes. In addition, it prevents phosphorylation of the cell cycle kinases CDK1, 2, 4, and 6, thereby disrupting uncontrolled cell cycle progression. Altogether, this may induce apoptosis, cause cell cycle arrest, inhibit DNA damage repair and inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc and beta-catenin, through the phosphorylation of RNA polymerase II." @default.